Equities research analysts predict that Karyopharm Therapeutics Inc (NASDAQ:KPTI) will post ($0.88) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Karyopharm Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.94) and the highest estimate coming in at ($0.80). Karyopharm Therapeutics reported earnings of ($0.65) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 35.4%. The business is scheduled to announce its next quarterly earnings report on Thursday, November 1st.
According to Zacks, analysts expect that Karyopharm Therapeutics will report full-year earnings of ($3.18) per share for the current fiscal year, with EPS estimates ranging from ($3.36) to ($2.96). For the next financial year, analysts anticipate that the business will post earnings of ($3.18) per share, with EPS estimates ranging from ($3.84) to ($2.55). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Tuesday, August 7th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.21. The company had revenue of $19.89 million during the quarter, compared to analysts’ expectations of $5.97 million.
Shares of KPTI stock opened at $15.55 on Friday. Karyopharm Therapeutics has a twelve month low of $9.00 and a twelve month high of $21.71. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of -5.34 and a beta of 3.75.
In related news, major shareholder Ltd Chione sold 251,468 shares of Karyopharm Therapeutics stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $20.94, for a total value of $5,265,739.92. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Sharon Shacham sold 12,500 shares of Karyopharm Therapeutics stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $19.31, for a total value of $241,375.00. Following the completion of the sale, the insider now owns 726,010 shares in the company, valued at $14,019,253.10. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,044,201 shares of company stock worth $20,667,401. Company insiders own 13.26% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in Karyopharm Therapeutics by 47.0% during the 2nd quarter. BlackRock Inc. now owns 4,055,634 shares of the company’s stock valued at $68,905,000 after purchasing an additional 1,297,571 shares in the last quarter. Palo Alto Investors LP boosted its stake in shares of Karyopharm Therapeutics by 3.8% during the 1st quarter. Palo Alto Investors LP now owns 3,679,978 shares of the company’s stock worth $49,385,000 after acquiring an additional 135,539 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Karyopharm Therapeutics by 51.5% during the 2nd quarter. Northern Trust Corp now owns 601,974 shares of the company’s stock worth $10,226,000 after acquiring an additional 204,680 shares in the last quarter. Emerald Advisers Inc. PA bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter worth $9,537,000. Finally, venBio Select Advisor LLC bought a new stake in shares of Karyopharm Therapeutics during the 1st quarter worth $7,524,000. Hedge funds and other institutional investors own 71.40% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Featured Story: Understanding each part of a balance sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.